COMPUTED DESCRIPTORS
| Molecular Weight | 2293.7 g/mol |
|---|---|
| XLogP3 | -11.3 |
| Hydrogen Bond Donor Count | 41 |
| Hydrogen Bond Acceptor Count | 33 |
| Rotatable Bond Count | 85 |
| Exact Mass | 2293.3582937 g/mol |
| Monoisotopic Mass | 2292.3549388 g/mol |
| Topological Polar Surface Area | 1080 Ų |
| Heavy Atom Count | 160 |
| Formal Charge | 0 |
| Complexity | 4890 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 20 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Onilcamotide is a cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.